Addendum
Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15
Report documents
-
Addendum
Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15
Dossier assessment
Adult patients with active psoriatic arthritis
Patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: hint of considerable added benefit.
Patients who have had an inadequate response or who have been intolerant to a prior therapy with biologic disease-modifying antirheumatic drugs (bDMARDs): added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.
Project details
- Project no.
- A21-81
- Commission
- Commission awarded on 09.06.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Venetoclax (previously untreated chronic lymphocytic leukaemia; combination with acalabrutinib with or without obinutuzumab) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed